Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Parkinson disease

Blood transcriptomics for Parkinson disease?

Parkinson disease (PD) affects up to 10 million people worldwide and is clinically diagnosed. Molecular phenotyping of patient samples might help to corroborate diagnosis, and a new study suggests that blood-based gene expression profiling might distinguish between patients with PD and those without. However, experience suggests that additional replication is needed.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Adler, C. H. et al. Low clinical diagnostic accuracy of early versus advanced Parkinson disease: clinicopathologic study. Neurology 83, 406–412 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2

    Shamir, R. et al. Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology 89, 1676–1683 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3

    Scherzer, C. R. et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl Acad. Sci. USA 104, 955–960 (2007).

    CAS  Article  PubMed  Google Scholar 

  4. 4

    Soreq, L., Israel, Z., Bergman, H. & Soreq, H. Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson's disease patients. J. Neuroimmunol. 201–202, 227–236 (2008).

    Article  PubMed  Google Scholar 

  5. 5

    Molochnikov, L. et al. A molecular signature in blood identifies early Parkinson's disease. Mol. Neurodegener. 7, 26 (2012).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6

    Santiago, J. A. & Potashkin, J. A. Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease. Proc. Natl Acad. Sci. USA 112, 2257–2262 (2015).

    CAS  Article  PubMed  Google Scholar 

  7. 7

    Santiago, J. A. & Potashkin, J. A. Blood biomarkers associated with cognitive decline in early stage and drug-naive parkinson's disease patients. PLOS ONE 10, e0142582 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Cummings, J. L. et al. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 134, 3146–3166 (2011).

    Article  PubMed  Google Scholar 

  9. 9

    Marek, K. et al. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629–635 (2011).

    Article  Google Scholar 

  10. 10

    Chen-Plotkin, A. S. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 84, 594–607 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Alice S. Chen-Plotkin.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen-Plotkin, A. Blood transcriptomics for Parkinson disease?. Nat Rev Neurol 14, 5–6 (2018).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing